Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Brain and Central Nervous System Tumors
Interventions: motexafin gadolinium, radiation therapy; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Renal Failure
Interventions: Selective cytopheretic device (SCD); Device
Lead sponsor: SeaStar Medical; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 4 more

Conditions: Advanced Malignancies
Interventions: MBG453, PDR001, Decitabine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Houston, Texas + 1 more

Conditions: Solid Tumors
Interventions: ALN-VSP02; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 7
States / cities: Scottsdale, Arizona • Boston, Massachusetts • Detroit, Michigan + 2 more

Conditions: Obesity
Interventions: sibutramine hydochloride monohydrate; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: North Chicago, Illinois

Conditions: Prostate Cancer
Interventions: ClariCore System; Device
Lead sponsor: Precision Biopsy, Inc.; Industry
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Interventions: Fabrazyme (agalsidase beta); Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 16 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 9
States / cities: Farmington, Connecticut • Coral Springs, Florida • Kansas City, Kansas + 6 more

Conditions: Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
Interventions: Sirolimus; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Best Practice, Exercise Counseling, Exercise Intervention, Magnetic Resonance Imaging, Neuropathy Assessment, Questionnaire Administration; Other · Procedure
Lead sponsor: University of Rochester NCORP Research Base; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 93
States / cities: Fresno, California • Martinez, California • Roseville, California + 70 more

Conditions: Major Depressive Disorder
Interventions: Agomelatine (AGO178C), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 47
States / cities: Birmingham, Alabama • Beverly Hills, California • Encino, California + 41 more

Conditions: Overactive Bladder
Interventions: Vibegron, Placebo; Drug
Lead sponsor: Urovant Sciences GmbH; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 1,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 75
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 64 more

Conditions: Prader-Willi Syndrome
Interventions: Placebo, Tesomet; Other · Drug
Lead sponsor: Saniona; Industry
Eligibility: 13 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease, Stroke, Traumatic Brain Injury
Interventions: Not listed
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 5,290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Aliso Viejo, California

Conditions: Prostate Cancer
Interventions: Degarelix; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 17
States / cities: Homewood, Alabama • Anaheim, California • Tarzana, California + 14 more

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Nitazoxanide; Drug
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 13 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Glaucoma, Open-Angle
Interventions: OMNI® Surgical System, iStent inject; Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Dothan, Alabama • Vineland, New Jersey

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Methylphenidate Transdermal System; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 18
States / cities: Scottsdale, Arizona • San Marcos, California • Boulder, Colorado + 15 more

Conditions: Glioblastoma Multiforme
Interventions: ICT-121 DC vaccine; Biological
Lead sponsor: Precision Life Sciences Group; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 6
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 3 more

Conditions: Congestive Heart Failure
Interventions: Placebo, Cinaciguat (BAY58-2667); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 6
States / cities: San Diego, California • Washington D.C., District of Columbia • Boston, Massachusetts + 3 more

Conditions: Bronchiectasis
Interventions: Ciprofloxacin (Cipro, BAYQ3939), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Little Rock, Arkansas • La Jolla, California • Denver, Colorado + 8 more

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured mixed population of dermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 7
States / cities: Tucson, Arizona • Santa Rosa, California • Denver, Colorado + 4 more

Conditions: Neuropathic Pain, Reflex Sympathetic Dystrophy, Peripheral Neuropathy, Post-herpetic Neuralgia, Spinal Cord Injury, Multiple Sclerosis
Interventions: Mild dose cannabis, Low dose cannabis, Cannabis; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Coronary Disease
Interventions: CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent; Device
Lead sponsor: Cordis US Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 1,701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: Durham, North Carolina • Cincinnati, Ohio

Conditions: Angelman Syndrome
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 5 more

Search by objective public record fields.

Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the Brain

Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement

A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.

ClariCore™ Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy

Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme

Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis

Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome

PRISM Registry: Pseudobulbar Affect Registry Series

Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer

Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients

A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle Glaucoma

Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma

Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667

Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis

A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931)

Effects of Vaporized Marijuana on Neuropathic Pain

Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)

Angelman Syndrome Natural History Study